Skip to main content
. 2021 Feb 22;16(3):384–395. doi: 10.2215/CJN.15260920

Figure 4.

Figure 4.

After an acute drop in eGFR between treatment commencement and week 3 in all baseline categories of albuminuria, canagliflozin attenuated annual eGFR decline from week 3 to last available measurement in every albuminuria subgroup. The absolute reduction in chronic eGFR slope was greatest in individuals with a UACR of >1000 to <3000 mg/g. SE, standard error.